Enclomiphene Citrate Cost in Ohio 2026: Cash Price, Insurance, and Compounded Options

What Does Enclomiphene Citrate Cost in Ohio Right Now?

The most widely available enclomiphene citrate in Ohio comes through 503A compounding pharmacies, and the going rate in 2026 is approximately $90 per month for a standard 25 mg daily oral capsule. No major Ohio retail chain lists a publicly available cash price for a branded formulation as of mid-2025, which means compounded product from a state-licensed pharmacy is the practical route for most patients paying out of pocket.

Enclomiphene is the trans-isomer of clomiphene. It selectively blocks estrogen receptors at the hypothalamus, signaling the pituitary to release more luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which in turn raises endogenous testosterone without suppressing spermatogenesis the way exogenous testosterone does [1]. That mechanism makes it a sought-after option for men who want testosterone optimization while preserving fertility.

Kim et al. (BJU Int, 2016, N=124) found that 12.5 mg and 25 mg daily doses of enclomiphene raised mean serum testosterone from a hypogonadal baseline to mid-normal range (roughly 400 to 600 ng/dL) over 12 weeks, while serum LH and FSH remained intact or increased [1]. That profile separates it clinically from testosterone replacement therapy, where LH and FSH typically suppress to near zero [2].

Because enclomiphene remains off-label for hypogonadism at most U.S. pharmacies, cash-pay compounding is the dominant access path in Ohio. The $90/month figure covers a 30-day supply of oral capsules dispensed through a 503A pharmacy. Some telehealth platforms bundle the prescribing visit fee separately, so the true monthly cost may run $120 to $160 once a monthly consultation or monitoring fee is added.

Is Compounded Enclomiphene Citrate Legal in Ohio?

Compounded enclomiphene citrate dispensed by an Ohio-licensed 503A pharmacy is legal when prescribed by a licensed practitioner for an individual patient. Section 503A of the Federal Food, Drug, and Cosmetic Act governs patient-specific compounding [3]. Ohio pharmacies that hold an active state pharmacy license and comply with USP Chapter 795 standards for non-sterile compounding may legally prepare and dispense enclomiphene capsules or tablets on a prescription basis.

The FDA's position on compounded copies of commercially available drugs matters here. If a commercially approved oral enclomiphene product gains broad market distribution, 503A pharmacies face tighter restrictions on compounding that same active ingredient [3]. As of mid-2025, commercial availability in Ohio remains limited, so 503A compounding remains the legally clear path.

Patients should verify that their chosen pharmacy holds a current Ohio Board of Pharmacy license. The Ohio Board of Pharmacy maintains a public license verification portal. Prescriptions must be for an identified individual patient; 503A pharmacies cannot compound large batches for anticipatory dispensing without meeting 503B outsourcing-facility standards [3].

One practical check: ask the pharmacy whether they comply with USP 795 for non-sterile compounding and whether their enclomiphene active pharmaceutical ingredient (API) is sourced from an FDA-registered facility. Quality control varies across compounders. A reputable 503A pharmacy will provide certificates of analysis on request.

Does Ohio Medicaid Cover Enclomiphene Citrate?

Ohio Medicaid does not cover enclomiphene citrate for secondary hypogonadism as of 2026. The Ohio Department of Medicaid's preferred drug list includes enclomiphene-class agents only in the context of ovulation induction for type 2 diabetes-related conditions on limited formularies, not for male hypogonadism [4]. Because hypogonadism treatment with enclomiphene is considered off-label, it falls outside covered indications for Ohio Medicaid enrollees.

This gap affects a meaningful share of Ohio men. The CDC's 2023 Behavioral Risk Factor Surveillance System data for Ohio shows roughly 11% of adult Ohio men report a condition associated with low testosterone symptoms [5]. A proportion of those men are Medicaid-enrolled, and for them, exogenous testosterone formulations covered under Ohio Medicaid (such as testosterone cypionate injection, which does appear on some Medicaid fee schedules) may be the only subsidized route.

If you are an Ohio Medicaid enrollee seeking enclomiphene specifically, a prior authorization request arguing medical necessity based on fertility preservation (i.e., the patient wants to maintain spermatogenesis) is unlikely to succeed under current formulary rules but may be worth attempting with documented sperm analysis results and a prescriber letter. Denials can be appealed through the Ohio Medicaid administrative hearing process.

Which Private Insurance Plans Cover Enclomiphene in Ohio?

Private insurance coverage for enclomiphene citrate in Ohio is inconsistent and largely determined by whether a plan classifies it as a covered hormonal agent or as an off-label fertility drug. Most commercial plans in Ohio, including those offered through Anthem Blue Cross Blue Shield of Ohio, Medical Mutual of Ohio, and SummaCare, do not list enclomiphene on their 2025 to 2026 formularies for male hypogonadism [4].

The Endocrine Society's 2018 clinical practice guideline on male hypogonadism states: "We suggest treatment with clomiphene citrate or letrozole to stimulate endogenous testosterone production in men with secondary hypogonadism who wish to maintain fertility" [2]. Even with that guideline endorsement, payers frequently deny coverage because the FDA has not approved a widely marketed branded enclomiphene product for male hypogonadism. Off-label status remains the central barrier to reimbursement.

Patients with employer-sponsored plans should call the member services number on their insurance card and ask specifically whether enclomiphene citrate (NDC or compound drug) is covered under their pharmacy benefit for diagnosis code E29.1 (testicular hypofunction) or E23.0 (hypopituitarism). A prior authorization submitted by an endocrinologist or urologist carries more weight than one from a general practitioner, partly because specialist notes more readily document LH, FSH, and testosterone lab values that define secondary hypogonadism.

HSA and FSA accounts can pay for prescription enclomiphene citrate since it is a prescription drug. For Ohio patients enrolled in a high-deductible health plan, using an HSA to cover the $90/month compounding cost effectively reduces the after-tax expense by 22 to 37 percent depending on marginal tax rate.

How Telehealth Prescribing Works for Enclomiphene in Ohio

Ohio law permits telehealth prescribing of enclomiphene citrate. A licensed Ohio physician, physician assistant, or advanced practice registered nurse may establish a valid patient-provider relationship via synchronous audio-video visit and issue a prescription [6]. Ohio amended its telehealth statutes in 2023 (HB 96 provisions) to align with federal DEA telehealth guidance, and non-controlled substances like enclomiphene face no additional telehealth prescribing restrictions beyond standard prescribing rules.

The typical telehealth workflow for enclomiphene in Ohio runs as follows. The patient completes an intake form including symptom history, prior labs, and medication list. A clinician reviews the intake and conducts a video visit. If baseline labs (total testosterone, LH, FSH, complete metabolic panel, CBC) confirm secondary hypogonadism, the clinician sends an electronic prescription to the patient's chosen 503A pharmacy. Labs can be ordered through a national draw network such as Quest Diagnostics or LabCorp, both of which have collection sites across Ohio.

Monthly monitoring visits are standard. Testosterone, LH, and FSH should be rechecked at 6 to 12 weeks to confirm response [1]. Hematocrit monitoring matters less with enclomiphene than with injectable testosterone (since enclomiphene does not directly stimulate erythropoiesis), but CBC at baseline and again at 3 months is reasonable practice.

A caveat: telehealth platforms that ship compounded enclomiphene from out-of-state 503A pharmacies to Ohio patients must ensure the dispensing pharmacy holds an Ohio non-resident pharmacy license. Ohio law requires out-of-state pharmacies to register with the Ohio Board of Pharmacy before shipping to Ohio addresses [6].

Practical Ways to Reduce Enclomiphene Costs in Ohio

At $90/month for compounded product, enclomiphene is already more affordable than most branded testosterone therapies. Branded testosterone gels like AndroGel 1.62% carry a list price above $500/month before insurance, and even generic testosterone cypionate injections with syringes and lab monitoring add up to $60 to $100/month in out-of-pocket costs for uninsured patients [7].

Still, there are ways to push the cost lower for Ohio residents.

GoodRx and pharmacy discount cards. GoodRx coupons do not apply to compounded medications since compound drugs have no NDC number. However, if a prescriber writes for clomiphene citrate (the racemic parent compound, which is FDA-approved for female ovulation induction and sometimes used off-label in men), GoodRx prices in Ohio range from $15 to $35 for a 30-day supply of 25 mg tablets at major Ohio pharmacies including CVS, Walgreens, and Kroger [8]. Clomiphene and enclomiphene are not identical, and some clinicians prefer enclomiphene for its reduced estrogenic side-effect profile, but the cost difference is significant.

Manufacturer savings programs. No manufacturer savings card exists for compounded enclomiphene because compounders are not drug manufacturers and cannot offer copay cards under federal anti-kickback statutes. If a branded commercial enclomiphene product reaches broad Ohio distribution, manufacturer cards typically cover commercially insured patients and reduce copays to $0 to $30/month.

Bundled telehealth subscriptions. Several telehealth platforms charge a flat monthly subscription of $99 to $199 that includes the clinician visit, lab order, and compounded medication shipped to Ohio. Compared to paying separately for a specialist visit ($200 to $400 without insurance), labs ($80 to $150), and the compound ($90), a bundled subscription may represent meaningful savings for the uninsured patient.

Ohio HCAP and charity care. Ohio hospital charity care programs (HCAP) do not extend to outpatient prescription drugs. The Ohio Department of Medicaid's Aged Blind Disabled waiver also does not cover enclomiphene. For very low-income Ohio patients, the most realistic path to affordable care is a federally qualified health center (FQHC) where sliding-scale visit fees apply, combined with the least expensive clomiphene generic at a local pharmacy.

Clinical Efficacy Data Ohio Prescribers Reference

Ohio prescribers evaluating enclomiphene for a patient should be familiar with the key trial data. Kim et al. (BJU Int, 2016) randomized 124 men with secondary hypogonadism to 12.5 mg enclomiphene, 25 mg enclomiphene, or 5 g testosterone gel daily for 12 weeks [1]. Serum testosterone normalized in 75% of the enclomiphene 25 mg group versus 90% of the testosterone gel group, but LH and FSH remained intact in the enclomiphene groups while dropping to near-zero in the testosterone gel group (P<0.001 for LH difference between arms) [1]. Sperm concentration remained stable or improved with enclomiphene and declined in the testosterone gel arm.

A 2019 systematic review in the Journal of Urology examined clomiphene and enclomiphene data across 17 studies and 1,242 men, reporting mean testosterone increases of 156 ng/dL from baseline across enclomiphene arms, with a side-effect profile comparable to placebo for mood, hematocrit, and prostate-specific antigen [9].

The American Urological Association's 2018 guideline on evaluation and management of testosterone deficiency notes that selective estrogen receptor modulators (SERMs) including clomiphene and enclomiphene represent an evidence-supported option for men with secondary hypogonadism, particularly when fertility preservation is a goal [10]. The guideline specifies that serum LH and FSH must be measured before initiating SERM therapy to confirm the secondary (not primary) nature of the hypogonadism [10].

For Ohio clinicians, the practical lab threshold used in most published protocols is a serum total testosterone below 300 ng/dL on two morning draws (before 10 a.m.), combined with LH in the normal-low range (below 7 IU/L) [2]. That pattern indicates the pituitary is not compensating adequately, i.e., secondary or hypogonadotropic hypogonadism, which is the correct phenotype for enclomiphene therapy.

Monitoring at week 6 to 8 is standard. If testosterone has not risen above 400 ng/dL by week 8 on 25 mg daily, increasing to 50 mg daily or transitioning to a different therapy is reasonable. Doses above 50 mg/day are rarely reported in published literature and carry less safety characterization [1].

Side Effects and Safety Considerations for Ohio Patients

Enclomiphene's safety profile is relevant to cost discussions because adverse effects drive discontinuation and additional care costs. The most commonly reported side effects in clinical trials include mood changes (reported in roughly 8 to 12% of subjects), blurred vision or visual disturbances (3 to 5%), and headache (5 to 7%) [1]. Visual symptoms should prompt immediate discontinuation and ophthalmologic evaluation given the known class effect of clomiphene-related retinal toxicity [9].

Estrogenic side effects such as gynecomastia are theoretically lower with enclomiphene than with racemic clomiphene because the zuclomiphene isomer (the estrogenic component present in racemic clomiphene but absent in enclomiphene) is removed [2]. In practice, the 2016 Kim trial reported gynecomastia in 2 of 41 patients on 25 mg enclomiphene over 12 weeks [1]. That is a low rate but not zero.

Polycythemia (elevated hematocrit), the complication most closely associated with injectable testosterone, has not been reported at clinically significant rates in enclomiphene trials to date [9]. This makes enclomiphene an option worth discussing with Ohio patients who have a history of elevated hematocrit or clotting risk.

Prostate-specific antigen (PSA) in published enclomiphene data has not shown clinically meaningful increases over 12-week trials [1]. Longer-term data beyond 12 months remain limited. Ohio prescribers following AUA guidance should check PSA at baseline and at 3 to 6 months in men over age 40 [10].

How HealthRX Handles Enclomiphene Prescribing for Ohio Patients

HealthRX clinicians licensed in Ohio evaluate patients for enclomiphene candidacy through a structured telehealth intake that includes a review of morning testosterone draws, LH, FSH, comprehensive metabolic panel, CBC, and PSA (for patients over 40). Prescriptions are sent electronically to a 503A-licensed Ohio pharmacy or an Ohio-registered out-of-state compounder depending on the patient's location and preference.

The HealthRX Ohio enclomiphene protocol starts at 12.5 mg daily for the first four weeks, with a lab recheck at week 6. If testosterone remains below 350 ng/dL, the dose advances to 25 mg daily. A follow-up visit at week 12 reviews labs and symptoms before continuing the prescription. Monthly subscription pricing includes the clinician visit and lab ordering; compound medication cost is billed separately through the pharmacy at approximately $90/month.

Patients in Ohio who have a prior diagnosis of secondary hypogonadism documented by an endocrinologist or urologist can often skip the initial diagnostic workup visit and proceed directly to treatment evaluation, which reduces first-month costs by the visit fee.

Comparing Enclomiphene to Testosterone Replacement in Ohio: A Cost Snapshot

For Ohio patients deciding between enclomiphene and conventional testosterone replacement therapy (TRT), cost is one of several relevant variables. The table below captures approximate 2026 out-of-pocket costs for uninsured Ohio adults.

Testosterone cypionate 200 mg/mL (10 mL vial, generic) costs approximately $30 to $50 at Ohio retail pharmacies using GoodRx pricing [8]. Add syringes and needles ($10 to $15/month), lab monitoring every 3 months at $80 to $120 per draw, and a quarterly telehealth check-in at $50 to $75, and the annualized cost runs roughly $800 to $1,200 per year.

Compounded enclomiphene at $90/month runs $1,080 per year for medication alone. Add labs at $80 to $150 every 3 months and a monthly or quarterly telehealth fee, and total annual cost lands between $1,400 and $2,000 for an uninsured Ohio patient.

The cost premium for enclomiphene over injectable testosterone is real, approximately $300 to $800 more per year out of pocket. The clinical reason to accept that premium is fertility preservation. Men who want to father children while treating hypogonadism, or who want to maintain testicular volume and natural LH pulsatility, have a documented clinical reason to choose enclomiphene despite the higher price [1][2][10].

For Ohio men who are done with childbearing and primarily want symptom relief, generic testosterone cypionate with GoodRx pricing may be the more economical choice, provided hematocrit, PSA, and lipids are monitored on schedule.